Clinical Trials
16 trialsNCT07615283 2026-05-29
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06137144 2026-05-19
PRIMAVERA
AstraZeneca
Phase 1/2 Recruiting
NCT03547700 2026-05-06
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT05255601 2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04390737 2026-01-30
Evaluate the Safety and Clinical Activity of HH2853
Haihe Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT06909877 2026-01-30
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Haihe Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT02264613 2026-01-13
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Aileron Therapeutics, Inc.
Phase 1/2 Completed
NCT04425070 2026-01-05
TOUCH
Antengene Corporation
Phase 1/2 Terminated
NCT07093710 2025-12-31
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT07288814 2025-12-17
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06421948 2025-12-05
Linperlisib Combined With Chidamide in Patients With PTCL
Henan Cancer Hospital
Phase 1/2 Recruiting
NCT02223208 2025-12-02
FIL_PTCL13
Fondazione Italiana Linfomi - ETS
Phase 1/2 Active not recruiting
NCT07209163 2025-10-06
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Ruijin Hospital
Phase 1/2 Not yet recruiting